4DMedical Limited, a global leader in respiratory imaging technology, is pleased to announce it has entered into a secured facility agreement with Pro Medicus Limited, a global leader in medical imaging software and solutions, to provide 4DMedical with $10M. The Facility Agreement includes security as collateral and the material terms of the Facility Agreement are set out in Annexure 1.
This strategic investment will provide 4DMedical with growth capital to accelerate its commercial pipeline for existing products while advancing CT:VQ towards regulatory clearance in the United States.
“Pro Medicus is a global leader in healthcare, and we are thrilled to receive their support at this pivotal moment in our journey. This strategic investment places us in a very strong position to take CT:VQ to market once it is cleared by the FDA,” said Andreas Fouras, MD, Founder and CEO at 4DMedical. “4D stands at a very exciting moment, with rapid growth in sites and scans month on month against a backdrop of falling costs. Add to this the growing momentum in the Philips partnership, and the shortening timeline to expected FDA clearance of CT:VQ, we are set for extremely strong performance over the coming months.”
About Pro Medicus
Pro Medicus is an ASX-listed global healthcare technology company specialising in medical imaging software and integrated informatics solutions. With over 30 years of experience, Pro Medicus has established itself as a trusted partner to major healthcare institutions worldwide, including Mayo Clinic, Johns Hopkins, and other leading hospitals and imaging centres across the U.S., Europe, and Australia.
About 4DMedical
4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.
At the heart of 4DMedical’s innovation is its patented XV Technology, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the company’s FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS) and its CT LVAS, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.
4DMedical’s solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.
In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of Imbio, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio’s AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical’s mission to redefine respiratory healthcare.
To learn more, please visit 4dmedical.com.
Originally announced July 31st, 2025
